BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Exponential Biotherapies Inc. (EBI) And CatchMabs Join Forces In Commercial Bacteriophage Production


10/19/2005 5:10:14 PM

AMSTERDAM, Netherlands, March 2 /PRNewswire/ -- Exponential Biotherapies' Food Safety Division and CatchMabs announce they have signed contracts for the large scale commercial production of bacteriophages.

Bacteriophages are "friendly" viruses that target and kill specific bacteria. They are abundant in the environment -- including in our food and water. Through use of the right phage strains, and in the right amounts, Exponential Biotherapies has developed a "green" approach to controlling bacterial pathogens in the food supply. The company has pioneered this approach, which enables food producers to protect their products without having to use agents (such as antibiotics) that can be harmful to health as well as to the environment.

"The commercially viable production of phages is an art as well as a science", says the Division's Chief Operating Officer, Dirk de Meester. "The combination of our specialized bacteriophage knowledge and their innovative production process is groundbreaking, and unique to the business".

"The collaboration with Exponential Biotherapies allows us to leverage our experience in producing affinity molecules and to expedite our investments in production capacity," says Dr. Peter Sijmons, CEO of CatchMabs. "This will further establish our position as large scale producer of inexpensive affinity proteins for which we use the same infrastructure."

About Exponential Biotherapies

Exponential Biotherapies Inc (EBI) is a privately held biopharmaceutical company focused on the development and commercialization of new anti-bacterial and anti-inflammatory agents (http://www.expobio.com/). Exponential Biotherapies' success is built on a unique combination of an international scientific network and excellent capabilities for product development, manufacturing and marketing. The company is solution-driven and selects those leads for food safety in which proprietary intellectual property can be leveraged rapidly from bench to market.

About CatchMabs

CatchMabs is a privately held company headquartered in Wageningen (Netherlands) that develops and produces designer affinity proteins for industrial applications based on its proprietary concept of iMabs(R) (industrial Molecular affinity bodies). CatchMabs establishes alliances with a select group of industries that can function as technology and development partners (http://www.catchmabs.com/).

Exponential Biotherapies Inc

CONTACT: Dirk de Meester, COO Food Safety of EBI FOOD SAFETY,+31-64-604-8503, fax, +31-84-223-7292, demeester@expobio.com; or Bob Berns,J.D., Chief Financial Officer of EBI, +1-818-314-2265, fax, +1-818-999-0764,bberns@expobio.com; or Peter Sijmons, Founder, CEO of CatchMabs,+31-31-746-7777, cell, +31-65-324-6095, fax, +31-31-746-7788,info@catchmabs.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->